UNSPSC 51294207: Reboxetine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 947S0YZ36I. European Medicines Agency schedules Reboxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15112MIG. Reboxetine generally arises in the molecular formula C19H23NO3.

UNSPSC 51294207 Reboxetine (Commodity) shows minimal recent activity aligned with its nominal scope; the three posted state and local opportunities involve naloxone kits, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which target reboxetine specifically. State and local governments do procure pharmaceutical products through this taxonomy, but the recent solicitations are broad-based pharmaceutical and OTC purchasing programs rather than single-drug acquisitions. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The work spans supply agreements for emergency response items, pharmacy benefit direct-contracting models, and comprehensive generic and OTC product catalogs distributed through authorized wholesalers.

Recent activity concentrates in Texas, Minnesota (serving multiple states including Oregon), and Florida. Seminole County, Florida posted an IFB (IFB60459723LAS, due Jul 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term with optional one-year renewal. The Texas HHS Commission issued an RFI (HHS0017013, posted Apr 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. MMCAP released an RFP (S1070000015802, due Mar 26, 2026) for generic multi-source pharmaceuticals and OTC products to be stocked through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026, weighted 75 percent on price competitiveness and requiring vendors to maintain relationships with at least two of three authorized wholesalers with chargeback systems. All solicitations require FDA compliance, Good Manufacturing Practices certification, and Drug Supply Chain Security Act adherence.